Evidence map›Paper›PMID 16168060›Full record

ArticleBMC biotechnology2005

Effects of DNA mass on multiple displacement whole genome amplification and genotyping performance.

Andrew W Bergen, Ying Qi, Kashif A Haque, Robert A Welch, Stephen J Chanock

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Whole-genome amplification enables accurate genotyping for microarray-based high-density single nucleotide polymorphism array.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2008
    Article
  19. A procedure for highly specific, sensitive, and unbiased whole-genome amplification.Proceedings of the National Academy of Sciences of the United States of America · 2008
    Article
  20. Performance of amplified DNA in an Illumina GoldenGate BeadArray assay.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andrew W BergenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. bergena@mail.nih.gov
Ying Qi
Kashif A Haque
Robert A Welch
Stephen J Chanock
National Institutes of Health · USNational Cancer Institute · US

Funding

Core Genotyping FacilityZ01CP010178 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI CHANOCK, STEPHEN J. · 2002 to 2008
$4.0M
D-serine/DsdCXA Control of E. coli UropathogenesisR01DK063250 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI WELCH, RODNEY A. · 2003 to 2013
$3.3M
MOLECULAR STUDY OF HOST RESPONSE/GENETIC RISK FACTORS OF INFECTION COMPLICATIONZ01SC010083 · SC · CLINICAL SCIENCES · PI CHANOCK, STEPHEN J · 1997 to 2007
$1.1M
Intramural NIH HHSNIDDK NIH HHS R01 DK063250
6 · The paper itself

Abstract

backgroundWhole genome amplification (WGA) promises to eliminate practical molecular genetic analysis limitations associated with genomic DNA (gDNA) quantity. We evaluated the performance of multiple displacement amplification (MDA) WGA using gDNA extracted from lymphoblastoid cell lines (N = 27) with a range of starting gDNA input of 1-200 ng into the WGA reaction. Yield and composition analysis of whole genome amplified DNA (wgaDNA) was performed using three DNA quantification methods (OD, PicoGreen and RT-PCR). Two panels of N = 15 STR (using the AmpFlSTR Identifiler panel) and N = 49 SNP (TaqMan) genotyping assays were performed on each gDNA and wgaDNA sample in duplicate. gDNA and wgaDNA masses of 1, 4 and 20 ng were used in the SNP assays to evaluate the effects of DNA mass on SNP genotyping assay performance. A total of N = 6,880 STR and N = 56,448 SNP genotype attempts provided adequate power to detect differences in STR and SNP genotyping performance between gDNA and wgaDNA, and among wgaDNA produced from a range of gDNA templates inputs.

resultsThe proportion of double-stranded wgaDNA and human-specific PCR amplifiable wgaDNA increased with increased gDNA input into the WGA reaction. Increased amounts of gDNA input into the WGA reaction improved wgaDNA genotyping performance. Genotype completion or genotype concordance rates of wgaDNA produced from all gDNA input levels were observed to be reduced compared to gDNA, although the reduction was not always statistically significant. Reduced wgaDNA genotyping performance was primarily due to the increased variance of allelic amplification, resulting in loss of heterozygosity or increased undetermined genotypes. MDA WGA produces wgaDNA from no template control samples; such samples exhibited substantial false-positive genotyping rates.

conclusionThe amount of gDNA input into the MDA WGA reaction is a critical determinant of genotyping performance of wgaDNA. At least 10 ng of lymphoblastoid gDNA input into MDA WGA is required to obtain wgaDNA TaqMan SNP assay genotyping performance equivalent to that of gDNA. Over 100 ng of lymphoblastoid gDNA input into MDA WGA is required to obtain optimal STR genotyping performance using the AmpFlSTR Identifiler panel from wgaDNA equivalent to that of gDNA.

Indexed as

Genetic TechniquesGenomeBiotechnologyCell LineDNADNA PrimersFalse Positive ReactionsGenotypeHumansLoss of HeterozygosityLymphocytesNeoplasmsNucleic Acid Amplification TechniquesOrganic ChemicalsPolymorphism, Single NucleotideQuality ControlDNADNA PrimersOrganic ChemicalsPicoGreen

Identifiers

PMID16168060
PMCPMC1249558
OpenAlexW1584451756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.